STOCK TITAN

HealthLynked (HLYK) 10-Q Filings

HLYK OTC

Here are the 10-Q quarterly reports from HealthLynked Corp (HLYK) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow HLYK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HLYK filings page.

Rhea-AI Summary

HealthLynked Corp. (HLYK) reported third-quarter 2026 revenue of $155,934, compared with $388,545 a year earlier, and a net loss of $888,892 versus $851,800. For the nine months ended September 30, revenue was $829,229, compared with $1,755,113, while net loss was $3,329,901 versus $2,603,777.

At September 30, 2026, cash was $16,594 and the working capital deficit was $1,416,099. The company used $964,510 in operating cash during the nine-month period. Management expects continued net losses and significant cash outflows for at least the next 12 months, and said it cannot meet obligations within one year of issuance without additional funding. It reported substantial doubt about continuing as a going concern through November 16, 2027.

In February 2026, the company refinanced prior debt payable to a trust controlled by Dr. Michael Dent, its Chief Executive Officer and Chairman, into a $5,715,812 secured convertible note bearing 12% interest and maturing February 2, 2029. The conversion price was adjusted to $2.75 per share in July; the note’s carrying value was $6,696,618 at September 30.

Rhea-AI Summary

HealthLynked Corp. reported declining activity and continued losses for the quarter ended June 30, 2026. Total revenue was $249,830, down from $592,360 a year earlier, and the net loss to common shareholders was $819,705, versus $701,038 in the prior-year quarter. For the first six months of 2026, revenue was $673,295 and the net loss to common shareholders was $2,477,356.

The balance sheet shows a very strained position. Total assets were $1,592,990 against total liabilities of $9,346,257, resulting in a shareholders’ deficit of $7,753,267. Cash was only $12,844 and the working capital deficit was $7,351,419. The company relies heavily on debt, including SBA disaster loans and multiple high-cost notes with original issue discounts, default conversion features, and derivative liabilities of $23,663.

Management stated there is substantial doubt about the company’s ability to continue as a going concern without additional funding, citing ongoing losses and expected cash outflows over at least the next 12 months. In February 2026, prior obligations to the CEO were refinanced into a new $5,715,812 secured convertible note at 12% interest and a $4.25 conversion price, generating a $1,328,069 gain on extinguishment of debt but also significant ongoing fair value volatility.

Rhea-AI Summary

HealthLynked Corp. reported weak first-quarter 2026 results, with total revenue of $423,465, down from $774,208 in the prior-year quarter. Patient service revenue and product revenue both decreased, while selling, general and administrative expenses rose to $847,281.

The company posted a net loss of $1,621,304 and a net loss to common shareholders of $1,657,651, or $0.57 per share, versus a $0.37 loss a year earlier. Cash was only $23,973 with a working capital deficit of $6,658,253 and shareholders’ deficit of $7,021,799. Management concluded there is substantial doubt about HealthLynked’s ability to continue as a going concern without additional funding.

Rhea-AI Summary

HealthLynked Corp. (HLYKD) reported lower sales and continued losses for the quarter ended September 30, 2025. Total revenue was $388,545 versus $590,124 a year earlier, as patient service, subscription, and product revenue all declined. For the first nine months of 2025, revenue was $1,755,113 compared with $2,389,434 in the prior-year period.

The company posted a quarterly net loss of $851,800 and a nine‑month net loss of $2,603,777, though both were smaller than the prior year. Operating expenses fell year over year, helped by the absence of a $716,000 impairment charge recorded in 2024 and lower practice and overhead costs.

HealthLynked’s balance sheet remains strained. As of September 30, 2025, cash was $10,911, total assets were $1,764,557, and shareholders’ deficit widened to $5,433,415. Current liabilities of $6,744,301 included significant related‑party convertible debt, third‑party notes, and lease obligations. Management disclosed a substantial doubt about the company’s ability to continue as a going concern through November 19, 2026 without additional capital.

During the period, HealthLynked executed a 1‑for‑100 reverse stock split, reducing outstanding common shares from 284,750,832 to 2,847,873, and later agreed to sell its BTG physical therapy practice assets for $125,000 in cash.